275 related articles for article (PubMed ID: 27057669)
41. B-cell receptor signaling in chronic lymphocytic leukemia.
Stevenson FK; Krysov S; Davies AJ; Steele AJ; Packham G
Blood; 2011 Oct; 118(16):4313-20. PubMed ID: 21816833
[TBL] [Abstract][Full Text] [Related]
42. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
43. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
Rickert RC
Nat Rev Immunol; 2013 Aug; 13(8):578-91. PubMed ID: 23883968
[TBL] [Abstract][Full Text] [Related]
44. Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies.
Lukas M; Velten B; Sellner L; Tomska K; Hüellein J; Walther T; Wagner L; Muley C; Wu B; Oleś M; Dietrich S; Jethwa A; Bohnenberger H; Lu J; Huber W; Zenz T
Leukemia; 2020 Nov; 34(11):2934-2950. PubMed ID: 32404973
[TBL] [Abstract][Full Text] [Related]
45. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
Puła A; Stawiski K; Braun M; Iskierka-Jażdżewska E; Robak T
Leuk Lymphoma; 2018 May; 59(5):1084-1094. PubMed ID: 28891366
[TBL] [Abstract][Full Text] [Related]
47. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma G; Johnson TP; Advani RH
Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
[TBL] [Abstract][Full Text] [Related]
48. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
Shukla A; Shukla V; Joshi SS
Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
[TBL] [Abstract][Full Text] [Related]
49. VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Härzschel A; Zucchetto A; Gattei V; Hartmann TN
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210016
[TBL] [Abstract][Full Text] [Related]
50. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Ten Hacken E; Gounari M; Ghia P; Burger JA
Leukemia; 2019 Feb; 33(2):287-298. PubMed ID: 30555163
[TBL] [Abstract][Full Text] [Related]
51. Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?
Allen JC; Talab F; Slupsky JR
Int J Hematol Oncol; 2016 May; 5(1):37-53. PubMed ID: 30302202
[TBL] [Abstract][Full Text] [Related]
52. Signal transduction inhibitor therapy for lymphoma.
Witzig TE; Gupta M
Hematology Am Soc Hematol Educ Program; 2010; 2010():265-70. PubMed ID: 21239804
[TBL] [Abstract][Full Text] [Related]
53. B-cell receptor signaling in the pathogenesis of lymphoid malignancies.
Bojarczuk K; Bobrowicz M; Dwojak M; Miazek N; Zapala P; Bunes A; Siernicka M; Rozanska M; Winiarska M
Blood Cells Mol Dis; 2015 Oct; 55(3):255-65. PubMed ID: 26227856
[TBL] [Abstract][Full Text] [Related]
54. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase.
Aslan B; Hubner SE; Fox JA; Taverna P; Wierda WG; Kornblau SM; Gandhi V
Haematologica; 2022 Jan; 107(1):292-297. PubMed ID: 34498444
[No Abstract] [Full Text] [Related]
55. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
ten Hacken E; Burger JA
Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
[TBL] [Abstract][Full Text] [Related]
56. Role of B cell receptor signaling in IL-10 production by normal and malignant B-1 cells.
Alhakeem SS; Sindhava VJ; McKenna MK; Gachuki BW; Byrd JC; Muthusamy N; Bondada S
Ann N Y Acad Sci; 2015 Dec; 1362(1):239-249. PubMed ID: 26096907
[TBL] [Abstract][Full Text] [Related]
57. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
58. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
Mansouri L; Sutton LA; Ljungström V; Bondza S; Arngården L; Bhoi S; Larsson J; Cortese D; Kalushkova A; Plevova K; Young E; Gunnarsson R; Falk-Sörqvist E; Lönn P; Muggen AF; Yan XJ; Sander B; Enblad G; Smedby KE; Juliusson G; Belessi C; Rung J; Chiorazzi N; Strefford JC; Langerak AW; Pospisilova S; Davi F; Hellström M; Jernberg-Wiklund H; Ghia P; Söderberg O; Stamatopoulos K; Nilsson M; Rosenquist R
J Exp Med; 2015 Jun; 212(6):833-43. PubMed ID: 25987724
[TBL] [Abstract][Full Text] [Related]
59. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
60. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
Rosenthal A
Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
